¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Ascorbic Acid Coated 96% Type SC"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • ketonic acid
    ÄÉÅæ»ê
  • lauric acid
    ·Î¸£»ê
  • leuconic acid
    ·ùÄÜ»ê
  • lichenic acid
    ÁöÀÇ»ê
  • linoleic acid
    ¸®³î·¹»ê
  • linolenic acid
    ¸®³î·»»ê
  • linolic acid
    ¸®³î»ê
  • lipoic acid
    ¸®Æ÷»ê
  • lactic acid
    Á¥»ê
  • mixed acid
    È¥ÇÕ»ê
  • maleic acid
    ¸»·¹»ê
  • malic acid
    ¸»»ê
  • mucic acid
    ¹Â½Å»ê
  • muramic acid
    ¹Â¶ó¹Í»ê
  • mycolic acid
    ¹ÌÄÝ»ê
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • linoleic acid
    ¸®³î·¹»ê
  • linolenic acid
    ¸®³î·»»ê
  • linolic acid
    ¸®³î»ê
  • lipoic acid
    ¸®Æ÷»ê
  • maleic acid
    ¸»·¹»ê
  • malic acid
    ¸»»ê
  • malonic acid
    ¸»·Ð»ê
  • mixed acid
    È¥ÇÕ»ê
  • mucic acid
    ¹Â½Å»ê
  • muramic acid
    ¹Â¶ó¹Í»ê
  • mycolic acid
    ¹ÌÄÝ»ê
  • neuraminic acid
    ´º¶ó¹Î»ê
  • neurostearic acid
    ½Å°æÁö¹æ»ê
  • nicotinic acid
    ´ÏÄÚÆ¾»ê
  • nitric acid
    Áú»ê
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • acid, dipicolinic
    µðÇÇÄݸ°»ê
  • acid, lipoteichoic
    ÁöÁúŸÀÌÄÚ»ê
  • acid, membrane teichoic
    ¸·¼ºÅ¸ÀÌÄÚ»ê
  • acid, muramic
    ¹Â¶ó¹Í»ê
  • acid, teichoic
    ŸÀÌÄÚ»ê
  • acid, teichuronic
    ŸÀÌÅ¥·Ð»ê
  • acid, ¥â-hydroxymyristic
    º£Å¸ÇÏÀ̵å·Ï½Ã¹Ì¸®½ºÆ¾»ê
  • acid-base buffer system
    »ê¿°±â¿ÏÃæ°è
  • acid-base compensation
    »ê¿°±â º¸»ó
  • acid-base indicator
    »ê¿°±âÁö½Ã¾à
  • acid-fast bacillus
    Ç×»ê±Õ(ù÷߫ж)
  • acid-fast stain
    Ç׻꼺 ¿°»ö
  • acid-fast stain
    Ç׻꼺¿°»ö(ù÷ß«àõæøßä)
  • acid<³ª> acidus
    »ê(ß«), »ê¼º(ß«àõ)ÀÇ.
  • adenylic acid deaminase
    ¾Æµ¥´Ò»ê Å»¾Æ¹Ì³ëÈ¿¼Ò.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • schizophrenia, hebephrenic type
    ÆÄ°úÇü Á¤½ÅºÐ¿­º´
  • schizophrenia, paranoid type
    ÆíÁýÇü Àü½ÅºÐ¿­º´
  • schizophrenia, simple type
    ´Ü¼øÇü Á¤½ÅºÐ¿­º´
  • schizophrenia, type I
    1Çü Á¤½ÅºÐ¿­º´
  • schizophrenia, type II
    2Çü Á¤½ÅºÐ¿­º´
  • scirrhous type
    °æÈ­Çü(Ìãûùû¡)
  • sensational type personality
    °¨°¢Çü ÀΰÝ.
  • sickle cell type
    °â»óÀûÇ÷±¸Çü
  • sinus venosus type
    Á¤¸Æµ¿Çü.
  • sinus venosus type
    Á¤¸Æµ¿Çü(¡­Ô×Çü)
  • skeleton type denture
    °ñ°ÝÈ­ÀÇÄ¡»ó(ÍéÌ«ûùëùöÍßÉ).
  • somatic type
    ½ÅüÇü
  • spaced type of deciduous dentition
    À¯±ØÇü À¯Ä¡¿­±Ã(êóÐÀû¡êáöÍæêÏá).
  • specific type
    ÇüƯÀ̼º(úþ÷åì¶àõ)
  • spectral type
    ½ºÆåÆ®·³Çü(¡­úþ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • essential amino acid index
    Çʼö(ù±âÎ) ¾Æ¹Ì³ë»ê(ß«) Áö¼ö(ò¦â¦)
  • essential fatty acid
    Çʼö Áö¹æ»ê (ù±âÎò·Û¸ß«)
  • ethylenediaminetetraacetic acid
    ¿¡Æ¿·»ÀÌ(ì£)¾Æ¹Î»ç(ÞÌ)¾Æ¼¼Æ®»ê(ß«)
  • ethylenedinitrolotetraacetic acid
    ¿¡Æ¿·»ÀÌ(ì£)³ªÀÌÆ®·Î»ç(ÞÌ)¾Æ¼¼Æ®»ê(ß«)
  • even-numbered fatty acid
    ¦¼ö Áö¹æ»ê(ß«)
  • fatty acid
    Áö¹æ»ê(ò·Û¸ß«)
  • fatty acid activating enzyme
    Áö¹æ»ê Ȱ¼ºÈ­ È¿¼Ò (ò·Û¸ß«üÀàõûùý£áÈ)
  • fatty acid activation
    Áö¹æ»ê Ȱ¼ºÈ­ (ò·Û¸ß«üÀàõûù)
  • fatty acid CoA ligase
    Áö¹æ»ê(ò·Û¸ß«) CoA ¶óÀ̰ÔÀ̽º
  • fatty acid oxidation
    Áö¹æ»ê »êÈ­ (ò·Û¸ß«ß«ûù)
  • fatty acid synthetase system
    Áö¹æ»ê ÇÕ¼º È¿¼Ò(ò·Û¸ß«ùêà÷ý£áÈ)½Ã½ºÅÛ
  • fatty acid thiokinase
    Áö¹æ»ê(ò·Û¸ß«) Ƽ¿ÀÄ«À̳×À̽º
  • folic acid
    Æú»ê(ß«)
  • folic acid coenzyme
    Æú»ê(ß«) º¸È¿¼Ò(ÜÍý£áÈ)
  • folic acid conjugate
    Æú»ê(ß«) Æ÷ÇÕü(øÙùêô÷)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
BAO-MAO basal acid output to maximal acid output [ratio]
cDNA circular deoxyribonucleic acid; complementary deoxyribonucleic acid
DPA D-penicillamine; Department of Public Assistance; diphenylalanine; dipicolinic acid; dipropylacetic ...
EAA electroacupuncture analgesia; Epilepsy Association of America; essential amino acid; excitatory amin...
FAA folic acid antagonist; formaldehyde, acetic acid, alcohol
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
AT1 Angiotensin type 1 receptor
AT2 Angiotensin II type 2
AT2 Angiotensin II type 2 receptor
AT(1) Angiotensin type 1
AT(1)R Angiotensin type 1 receptor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • dialuric acid
    ´ÙÀ̾˿ä»ê
    °áÁ¤¼­ÀÇ »ê. ¾Ë·Ï»êÀ¸·ÎºÎÅÍ ¾ò´Â´Ù.
  • diatrizoic acid
    ´ÙÀÌ¾ÆÆ®¶óÀÌÁ¶»ê
    ¹æ»ç¼± Á¶¿µÁ¦ Á¦Á¶¿¡ ¾²ÀδÙ.
  • dihydroxystearic acid
    ´ÙÀÌÇÏÀ̵å·Ï½Ã ½ºÅ׾Ƹ°»ê
    ¿Ã·¹ÀλêÀÇ »êÈ­·Î ¾òÀ¸¸ç, ÇǸ¶ÀÚÀ¯¿¡¼­ ¹ß°ßµÈ´Ù.
  • esophageal acid infusion test
    ½Äµµ»ê ÁÖÀÔ ½ÃÇè
  • essential amino acid
    Çʼö ¾Æ¹Ì³ë»ê
    ´Ü¹éÁúÀÇ ±âº» ±¸¼º ´ÜÀ§. ´Ü¹éÁúÀº ü³»¿¡¼­ ¾Æ¹Ì³ë»êÀ¸·Î ºÐÇØµÇ°í ³ª¼­ Èí¼ö, ÀÌ¿ëµÈ´Ù. µû¶ó¼­ ´Ü¹éÁúÀÇ ¿µ¾ç°¡´Â ±× ¼Ó¿¡ ÇÔÀ¯µÇ´Â ¾Æ¹Ì³ë»êÀÇ Á¾·ù¿Í ¾ç¿¡ ÀÇÇÏ¿© Á¤ÇØÁø´Ù. ¾Æ¹Ì³ë»êÀº µ¿¹°ÀÇ Ã¼³»¿¡¼­ ´Ù¸¥ ¾Æ¹Ì³ë»êÀ¸·ÎºÎÅÍ ¸¸µé¾îÁö´Â °Í°ú, ü³»¿¡¼­´Â ÇÕ¼ºµÇÁö ¾Ê°í À½½ÄÀ¸·Î ¼·ÃëµÇ¾î¾ß ÇÏ´Â °ÍÀÌ ÀÖ´Ù. µû¶ó¼­ ¼·ÃëÇÏÁö ¾ÊÀ¸¸é ¿ÏÀüÇÑ ´Ü¹éÁúÀÌ µÇÁö ¾Ê´Â´Ù. ÀÌ·¸°Ô ü³»¿¡¼­ ÇÕ¼ºÇÒ ¼ö ¾ø´Â ¾Æ¹Ì³ë»êÀ» Çʼö ¾Æ¹Ì³ë»ê ¶Ç´Â ºÒ°¡°á ¾Æ¹Ì³ë»êÀ̶ó°í ÇÑ´Ù. Çʼö ¾Æ¹Ì³ë»êÀÇ Á¾·ù´Â µ¿¹°ÀÇ Á¾·ù³ª ¼ºÀå ½Ã±â¿¡ µû¶ó ´Ù¸£Áö¸¸, ¼ºÀÎÀÇ °æ¿ì¿¡´Â ´ÙÀ½ÀÇ 8Á¾ÀÌ´Ù. À̼ҷù½Å, ·ù½Å, ¸®½Å, Æä´Ò¾Ë¶ó´Ñ, ¸ÞƼ¿À´Ñ, Æ®·¹¿À´Ñ, Æ®¸³ÅäÆÇ, ¹ß¸°ÀÌ´Ù. ¾î¸°¾ÆÀÌÀÇ °æ¿ì¿¡´Â ¿©±â¿¡ È÷½ºÆ¼µòÀÌ ´õÇØÁø´Ù.
  • essential fatty acid
    Çʼö Áö¹æ»ê
    °íµîµ¿¹°ÀÇ ¼ºÀå ¶Ç´Â °Ç°­ »óÅÂÀÇ À¯Áö¸¦ À§ÇÏ¿© ü¿Ü·ÎºÎÅÍ ¼·ÃëÇØ¾ß ÇÒ Áö¹æ»ê. ºñŸ¹Î F¶ó°íµµ ÇÑ´Ù. Áö¹æÀº ü³»¿¡¼­ ÁÖ·Î ¿¡³ÊÁö¿øÀÌ µÇ¹Ç·Î ´Ù¸¥ °ÍÀ¸·ÎºÎÅÍ Ä®·Î¸®¸¦ ÃëÇϸé Áö¹æÀº ÇÊ¿ä¾øÁö ¾ÊÀº°¡ ÇÏ´Â Àǹ®ÀÌ »ý±ä´Ù. ±×·¯³ª À½½Ä ¼Ó¿¡ Áö¹æÀÌ ÀüÇô ¾øÀ¸¸é µ¿¹°ÀÇ ¼ºÀåÀÌ Á¤ÁöÇÏ°í Æ¯À¯ÇÑ ÇǺο°ÀÌ »ý±ä´Ù. ÀÌ Áõ¼¼´Â ¸®³î»ê, ¸®³î·»»ê, ¾Æ¶ó۵·»ê Áß ¾î´À °ÍÀ» ÇÔÀ¯ÇÏ´Â Áö¹æÀ» Åõ¿©Çϸé Ä¡À¯µÈ´Ù. ±×·¡¼­ À̵é Áö¹æÀ» ¾Æ¹Ì³ë»êÀÇ ¿¹¿¡ µû¶ó Çʼö Áö¹æ»êÀ̶ó°í ÇÑ´Ù. ÀÌ»óÀÇ ¼¼ °¡Áö Áö¹æ»ê Áß¿¡¼­ ¸®³î»êÀº ÀϹÝÀûÀÎ À¯Áö¿¡ ³Î¸® ÇÔÀ¯µÇ¾î ÀÖÀ¸¹Ç·Î, º¸ÅëÀÇ Áö¹æÀ» ¼·ÃëÇϸé Áö¹æ»êÀÌ °áÇÌÇÏ´Â ÀÏÀº ¾ø´Ù.
  • ethacrynic acid
    ¿¡Å¸Å©¸°»ê
  • ethylene-diamin tetra-acetic acid
    ¿¡Æ¿·»µð¾Æ¹Î »ç-¾Æ¼¼Æ®»ê
    ¹é»öÀÇ ºÐ¸»·Î Á߱ݼÓ. ¾ËÄ®¸®Åä ±Ý¼Ó µî°ú È­ÇÕÇÏ¿© Àß ³ì´Â ¸Å¿ì ¾ÈÁ¤µÈ Ű·¹ÀÌÆ® È­ÇÕ¹°À» ¸¸µé°í, ¹æ»ç¼º ¿ø¼ÒÀÇ Å»¿À¿°. ¹°ÀÇ °æµµ ºñ»ö ºÐ¼®. ±Ý¼ÓÀÇ ¿ë·® ºÐ¼® µî¿¡ »ç¿ëµÇ¸ç, ÃÖ±Ù¿¡´Â Ç÷¾×À» ÀúÀåÇϴµ¥ ÷»çÇϸé Ç×ÀÀ°í¼º°ú º¸Á¸ ±â°£ÀÇ ¿¬ÀåÀ» °¡´ÉÄÉ ÇÑ´Ù´Â °ÍÀÌ ÆÇ¸íµÇ¾ú´Ù.
  • fatty acid cyclooxygenase
    Áö¹æ»ê »çÀÌŬ·Î¿Á½ÃÁö³×À̽º
  • folic acid antagonist
    ¿±»ê ±æÇ×Á¦
  • folic acid deficiency anemia
    ¿±»ê °áÆð¼º ºóÇ÷
  • formic acid
    Æ÷¸§»ê, °³¹Ì»ê, ÀÇ»ê
  • formiminoglutamic acid
    Æ÷¸£¹Ì¹Ì³ë±Û·çŸ¹Í »ê
    ±Û·çŸ¹Î»êÀÌ È÷½ºÆ¼Æ¾À¸·Î ºÐÇØµÇ´Â °ú Á¤ÀÇ Áß°£ »ê¹°ÀÌ´Ù.
  • free acid
    À¯¸® »ê
  • free fatty acid
    À¯¸® Áö¹æ»ê
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
type 6 glycogenosis Glycogenosis due to hepatic glycogen phosphorylase deficiency, resulting in accumulation of glycogen of normal chemical structure in liver and leukocytes.
Synonym: hepatophosphorylase deficiency glycogenosis, Hers' disease.
(05 Mar 2000)
type 7 glycogenosis Phosphofructokinase deficiency of muscle resulting in muscle cramps and myoglobinuria on extreme exertion. The clinical picture resembles type 5 glycogenosis.
(05 Mar 2000)
type A behaviour A behaviour pattern characterised by aggressiveness, ambitiousness, restlessness, and a strong sense of time urgency; associated with increased risk for coronary heart disease.
(05 Mar 2000)
type a personality Established behaviour pattern characterised by excessive drive and ambition, impatience, competitiveness, sense of time urgency, and poorly contained aggression.
(12 Dec 1998)
type B behaviour A behaviour pattern characterised by the absence or obverse of type A behaviour characteristics.
(05 Mar 2000)
type culture A type strain of microorganism preserved in a culture collection as the standard.
(05 Mar 2000)
type genus <zoology> The type of a taxon at the family group level - the nominal genus.
(09 Jan 1998)
type horizon <zoology> The geological stratum from which the name-bearing type of a nominal species or subspecies was collected.
(09 Jan 1998)
type host <zoology> The host species with which the name-bearing type of a nominal species or subspecies was associated.
(09 Jan 1998)
type I acrocephalosyndactyly <paediatrics> A usually inherited disorder characterised by premature closing of the cranial suture lines resulting in a peaked shaped head and abnormal facial appearance.
Since it is usually autosomal dominant one or both parents also have the disorder. Surgery is used to correct skull and facial abnormalities.
Inheritance: autosomal dominant.
(29 Dec 1997)
type I cells Highly attentuated squamous cell's that form the gas-permeable epithelium lining the alveoli of the lungs.
Synonym: type I cells.
(05 Mar 2000)
type I collagen The most abundant collagen, which forms large well-organised fibrils having high tensile strength.
(05 Mar 2000)
type I diabetes A chronic condition in which the pancreas makes little or no insulin because the beta cells have been destroyed. The body is then not able to use the glucose (blood sugar) for energy. IDDM usually comes on abruptly, although the damage to the beta cells may begin much earlier. The signs of IDDM are a great thirst, hunger, a need to urinate often, and loss of weight. To treat the disease, the person must inject insulin, follow a diet plan, exercise daily, and test blood glucose several times a day. IDDM usually occurs in children and adults who are under age 30. This type of diabetes used to be known as juvenile diabetes, juvenile-onset diabetes, and ketosis-prone diabetes.
(09 Oct 1997)
type I diabetes mellitus <endocrinology> A severe metabolic disorder which has an abrupt onset before the age of twenty. In it, an insulin deficiency prevents the body from using carbohydrates properly and forces it to rely mainly on protein metabolism.
Treatment of the disease includes strict dietary regulation and mandatory insulin injections.
(09 Oct 1997)
type I dip Early deceleration of the foetal heart rate at the height of uterine contraction, as displayed on a foetal monitor graph.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
ÅëÇÕ°Ë»ö ¿Ï·á